US8685445B2 - Enteric composition for the manufacture of soft capsule wall - Google Patents
Enteric composition for the manufacture of soft capsule wall Download PDFInfo
- Publication number
- US8685445B2 US8685445B2 US10/529,984 US52998403A US8685445B2 US 8685445 B2 US8685445 B2 US 8685445B2 US 52998403 A US52998403 A US 52998403A US 8685445 B2 US8685445 B2 US 8685445B2
- Authority
- US
- United States
- Prior art keywords
- soft capsule
- capsule shell
- enteric soft
- enteric
- film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Definitions
- the present invention relates to enteric preparations, More particularly, the invention relates to enteric solid dosage forms made using a gel mass comprising a film-forming, water-soluble polymer, an acid-insoluble polymer, and, optionally, other ingredients such as plasticizers, colors, and flavors.
- the invention further provides a direct method for manufacturing enteric preparations without need for coating.
- enteric dosage forms are well known to skilled personnel. Such dosage forms have been explained and reviewed in reference works, e.g., in Remington's Pharmaceutical Sciences, 18 th edition, Mack Publishing Co., Easton, Pa. (1990). Enteric dosage forms are desirable, either to protect the content of the dosage form from the gastric conditions or to protect the gastric tissue from an irritant material contained in the enteric dosage form. A further use for enteric dosages is prevention of a lasting, unacceptable mouth odor resulting from ingestion of substances like garlic or fish oil. Enteric dosage forms are also used to provide slow or delayed release of a substance.
- enteric or gastro-resistant preparations To fulfill the compendium definition requirement for enteric or gastro-resistant preparations, these preparations have to pass specific compendia tests.
- the enteric or gastro-resistant property is obtained only if the enteric dosage form does not dissolve or disintegrate in gastric acidity for a specified amount of time (usually two hours in 0.1 N hydrochloric acid at 37° C.). Further, the enteric dosage forms must release their contents in simulated intestinal environments (e.g., in buffers of pH values at about 6.8 within certain time periods). Detailed evaluation techniques are described in national and international pharmacopoeia such as United States Pharmacopoeia.
- enteric dosage forms The majority, if not all, of the enteric dosage forms currently in use are produced by a film-coating process, where a thin film layer of acid-insoluble (enteric) polymer is accumulated on the surface of an pre-manufactured dosage form. Dosage forms coated in this manner have been mainly tablets and, to a lesser extent, hard or soft capsules.
- the enteric coating method involves spraying of an aqueous or organic solution or a suspension of enteric polymers onto tumbling or moving tablets or capsules, accompanied by drying using hot air.
- Enteric dosage forms made by coating suffer from various process-related problems and defects that affect their performance or appearance. For example, “orange peel” surface formation, also known as surface roughness, mottling, or lack of surface homogeneity may result. And more seriously, coat integrity failure may occur, such as in cases of cracking or flaking off of the coating. All coatings present inherent problems, including possible uneven distribution of the coating ingredients, which can easily happen under the multivariate coating process.
- enteric coatings are shared by all enteric dosage forms such as tablets and capsules.
- problems faced during coating of capsules are even more critical, due to the delicate and heat sensitive nature of the soft elastic capsule shell. Both hard and soft capsules can easily undergo agglomeration and distortion due to the heat-sensitive shell composition.
- the smoothness and elasticity of the capsule surface make it difficult to form an intact adhering enteric coat without careful sub-coating step to improve the surface for coating.
- a further disadvantage of enteric coating for soft capsules is the loss of the normally shiny and clear appearance of capsule gelatin shells.
- the elegant, clear gelatin shell has been a significant reason for soft capsule popularity and acceptance. In addition to the undesirable surface texture modifications usually caused by coating, most accepted aqueous enteric polymer preparations result in opaque capsules.
- enteric soft gelatin capsules While different attempts have been tried to improve the manufacture of enteric soft gelatin capsules via coating, the inherent disadvantages in the coating process amplify the necessity for a better way of manufacturing enteric soft capsules, ideally, without coating. Enteric coatings (both sub-coating and over-coatings) and enteric polymers are discussed or suggested generally in U.S. Pat. Nos. 4,518,433, 4,816,259, and 5,330,759. None of these references, however, teach or suggest the invention as set forth herein.
- a gel mass composition that can be used to manufacture enteric oral dosage forms such as tablets or capsules, without the need of coating.
- a second aspect of this invention is a filled enteric soft capsule that does not require enteric coating or cross-linking to gain its enteric character.
- fill materials can be hydrophilic or hydrophobic in nature. Fill materials can also be liquid, solid or a combination thereof.
- a third aspect of this invention is a soft capsule enteric shell composition that contains a film-forming polymer, an acid-insoluble polymer, and, optionally, plasticizers, colors, and/or other conventionally accepted pharmaceutical additives.
- the gel mass composition of the invention avoids significant loss of physical strength or viscosity of the film-forming polymer.
- a fourth aspect of this invention is a process of preparing a gel mass from which the enteric capsule shell is made. According to the process of this aspect of the invention, an alkali is used at a level allowing dissolution of the acid-insoluble polymer without negatively affecting the film-forming polymer integrity, its physical strength, or its viscosity.
- a fifth aspect of this invention is a process of manufacturing filled enteric soft capsules using cast gel mass and a rotary die encapsulation machine, such as that disclosed in U.S. Pat. Nos. 5,146,730 and 5,459,983, incorporated herein by reference and commonly owned by the assignee of this application.
- a sixth aspect of this invention is production of clear enteric soft capsules.
- a seventh aspect of this invention is the production of transparent, yet colored, enteric soft capsules.
- An eighth aspect of the invention is the use of the foregoing aspects for delivering food and medicine.
- the gel mass compositions of this invention are further useful to manufacture enteric solid oral dosage forms such as tablets, and hard and soft capsules without the conventional coating technique.
- a preferred method of manufacturing enteric tablets with this invention is to use enrobement techniques and a rotary die as described in U.S. Pat. Nos. 6,482,516 and 5,459,983, and 5,146,730, all fully incorporated herein by reference.
- Gel compositions of this invention are also useful to make clear or opaque hard capsules using regular equipment known in the art.
- the present invention relates to a gel mass composition
- a gel mass composition comprising a film-forming, water-soluble polymer, an acid-insoluble polymer, and, optionally, at least one plasticizer, an optional coloring agent and an aqueous solvent.
- the gel mass is useful in manufacturing enteric soft or hard capsules, or enteric tablets without coating.
- the film-forming, water-soluble polymer can be of proteinaceous nature, such as gelatin.
- the gelatin is extracted from animal bones or skins, and has about 100 to about 250 blooms.
- the film-forming, water-soluble polymer can be of carbohydrate nature such as hydroxypropyl methylcellulose or methyl cellulose.
- the acid-insoluble polymer can also be selected from the group consisting of acrylic and methacrylic acid copolymers, cellulose acetate esters such as phthalate, butyrate, hydroxypropyl methyl cellulose phthalate, and salts thereof.
- the shell composition of the invention can contain at least one plasticizer selected from the from the group consisting of sorbitol, glycerol, polyethylene glycol, poly-alcohols with 3 to 6 carbon atoms, citric acid, citric acid esters such as triethyl citrate, and combinations thereof.
- the solvent used can be water or aqueous solution of alkalis, such as ammonia, sodium hydroxide, potassium hydroxide, ethylene diamine, hydroxylamine, tri-ethanol amine, or hydroalcoholic solutions of the same.
- alkali can adjusted such that the final pH of the gel mass is less than or equal to about 9.0 pH units. In another embodiment, the alkali is adjusted such that the pH does not exceed 8.5. In yet another embodiment, the alkali is adjusted such that the pH does not exceed 8.0.
- the alkali can be a volatile alkali such as ammonia or ethylene-diamine.
- compositions of the invention are characterized by a consistency compatible with desirable process handling, such as rotary die processing for capsule formation.
- desirable process handling such as rotary die processing for capsule formation.
- the compositions of the invention avoid undue degradation of the film-forming, water-soluble polymer by avoiding excessively alkaline conditions during processing.
- the invention also relates to a process of manufacturing a shell composition into soft capsules.
- the process includes preparing a solution comprising a film-forming, water-soluble polymer and an acid-insoluble polymer and mixing with appropriate plasticizers to form a gel mass; casting gel mass into films or ribbons using heat-controlled drums or surfaces; and manufacturing a soft capsule using rotary die technology.
- the thickness of the films or ribbons is from about 0.015 inches to about 0.050 inches. In one embodiment, the thickness is about 0.020 inches.
- the moisture content of the shell composition can be from about 2% to about 10%.
- the moisture content can also be from about 4% to about 8%.
- the moisture content of particular embodiments is about 8%.
- the invention also relates to an enteric gel composition having an enteric polymer to film-former polymer ratio of from about 20:80 to about 45:55.
- the invention also relates to an enteric gel composition having a plasticizer to polymer ratio from about 10% to about 50% of the polymer weight. In one embodiment, the ratio is about 25%.
- Capsules prepared in accordance with the methods of the invention can be used to contain a hydrophilic fill solution or suspension containing polyethylene glycol.
- the fill composition can be a hydrophobic solution or suspension, such as vegetable oils or shortening, or waxes, or combinations thereof.
- the present invention provides enteric, gel mass compositions that do not require cross-linking to achieve the desired enteric properties.
- Cross-linking treatments can cause potential toxicity concerns, and can lead to an uncontrolled process which lead to a product subject to deterioration over time. Further, such cross-linking adds an additional step to the manufacturing process.
- This invention discloses a composition, process of manufacture and use of enteric oral solid dosage forms, namely tablets, and hard and soft capsules that do not require a coating or cross-linking in order to possess enteric properties.
- the gel mass of this invention can be made by mixing a film-forming polymer with an acid-insoluble polymer, and plasticizing materials to form a homogeneous mixture, in presence of a solvent.
- the invention provides an acid-insoluble polymer within the film-former mass that renders the total mass an enteric material, at relatively low concentrations of the acid-insoluble polymer (from about 8% to about 20% of the total wet gel mass) and without the need of excessive amounts of alkali, thus avoiding degradation or weakening of the film-forming polymer.
- the ratio of acid-insoluble polymer to film-forming polymer is greater than about 1:4.
- Films made by casting the final gel mass do not dissolve or disintegrate in acids, such as 0.1 M hydrochloric acid, despite the fact that the majority of shell ingredients (more than 50%) normally dissolve in, or are miscible with, acids. Enteric films made using the disclosed compositions remain substantially intact in hydrochloric acid. Further, enteric films of this invention reduce migration of small molecules such as methylene blue through them in acidic environments. In another embodiment, the final gel mass provides films of increased strength without substantially compromising film elasticity. Moreover, casting films according to the invention are able to be sealed at normal temperature range typically used for making softgel capsules (from about 80° F. to about 105° F.) or can be used to surround or enrobe tablets to make them enteric. The gel masses can also be cast around pins to form two-piece hard capsules as illustrated in Remington's Pharmaceutical Sciences, 18 th edition, published by Mack Publishing Co., Easton, Pa. (1990)
- film-former polymers that are useful in this invention can be of natural origin, preferably gelatin, or of synthetic nature such as hydroxypropyl methyl cellulose.
- acid-insoluble polymers are cellulose acetate phthalate (CAP), cellulose acetate butyrate, hydroxypropyl methyl cellulose phthalate, algenic acid salts such as sodium or potassium alginate, shellac, acrylic acid-methacrylic acid copolymers (available under the trade name of EUDRAGIT (Rohm America Inc., Piscataway, N.J.) as powder or 30% aqueous dispersion, or under the trade name of EASTACRYL as 30% dispersion (Eastman Chemical Company, Kingsport, Tenn.), and sodium alginate.
- Acrylic-methacrylic acid copolymers are particularly stable and may be preferred in some embodiments. Acid-insoluble polymers specifications are detailed in the United States Pharmacopoeia.
- Useful plasticizers according to the invention are glycerol, sorbitol, polyethylene glycol, citric acid, citric acid esters, such as tri-ethyl citrate, or combinations thereof.
- the composition ratio between the film-former and the acid-insoluble polymer is adjusted so that the gel mass can be made into soft capsules. Without being limited to any mechanism of performance, it has been discovered that enteric capsules can be made with an acid-insoluble polymer comprising as little as about 8% of the total content of the wet shell mass, and as high as about 30% of the total wet shell mass.
- the weight ratio range of acid-insoluble polymer/film-former polymer is from about 25% to about 50%. The range can be from about 30% to about 40%.
- enteric gel masses can be made by dissolving the acid-insoluble polymer powder in aqueous solution of an alkali such as ammonia, sodium hydroxide, or potassium hydroxide, or liquid amines such as tri-ethanol amine or ethylene diamine.
- the amount of alkali is adjusted to give a final pH value of the gel mass less than or equal to about 9.0 pH units. In one embodiment, the final pH does not exceed 8.5. Volatile alkalis such as ammonia and ethylene diamine are preferred.
- the film-former can then be wetted by the plasticizer and mixed with the acid-insoluble gel to make a final homogeneous mix in a heat-controlled vessel and can be degassed by using vacuum.
- the alkali concentrations do not require an additional step such as heating or neutralizing with acid in order to neutralize the gel mass or the finished capsules.
- the enteric gel can be made by using a ready-made aqueous dispersion of the acid-insoluble polymer by adding alkaline materials such as ammonium, sodium, or potassium hydroxides or other alkalis that will cause the acid-insoluble polymer to dissolve, such as triethanol amine or ethylene diamine or a combination thereof.
- alkaline materials such as ammonium, sodium, or potassium hydroxides or other alkalis that will cause the acid-insoluble polymer to dissolve, such as triethanol amine or ethylene diamine or a combination thereof.
- the plasticizer-wetted, film-forming polymer can then be mixed with the solution of the acid-insoluble polymer.
- acid-insoluble polymers in the form of salts of the above-mentioned bases or alkalis can be dissolved directly in water and mixed with the plasticizer-wetted, film-forming polymer.
- the enteric composition of the invention comprising a film-forming polymer (e.g., gelatin or a synthetic polymer) and at least one enteric, acid-insoluble polymer, can be used to contain a fill that is liquid, semi-solid, or solid.
- a film-forming polymer e.g., gelatin or a synthetic polymer
- enteric, acid-insoluble polymer e.g., a fill that is liquid, semi-solid, or solid.
- a gel mass was made according to the formula below.
- the acid-insoluble polymer, EUDRAGIT L 100 was dissolved in the water-alkali vehicle, and triethyl citrate was then added.
- the film-forming polymer, gelatin (lime bone, 150 bloom) was mixed with the plasticizer, glycerol, and added to the enteric polymer solution, mixed for 2 hours and kept overnight at 60° C.
- Example 1 Gel mass of Example 1 was cast as a ribbon with 0.03′′ thickness on a cold drum (10° C. to 13° C.). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration testing as per the requirement of current USP.
- Example 1 Gel mass of Example 1 was cast into a ribbon with 0.03′′ thickness on a cold drum (10° C. to 13° C.). This ribbon is utilized for encapsulation of medium chain tryiglyceride oil using 12 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirements of current USP.
- Example 1 Gel mass of Example 1 was casted as a ribbon with 0.03′′ thickness on a cold drum (10° C. to 13° C.). This ribbon is utilized for encapsulation of medium chain tryiglyceride oil using 20 oblong die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirements of current USP.
- Example 1 Gel mass of Example 1 was cast as a ribbon with 0.03′′ thickness on a cold drum (10° C. to 13° C.). This ribbon is utilized for encapsulation of above mentioned fill using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirements of current USP.
- Example 1 Gel mass of Example 1 was cast into a ribbon with 0.03′′ thickness on a cold drum (10° C. to 13° C.). This ribbon is utilized for encapsulation of above mentioned fill using 7.5 oval die. Capsules were dried and subjected to dissolution/disintegration analysis as per the requirements of current USP.
- Gel mass of example 1 was casted as a ribbon with 0.03′′ thickness on a cold drum (10° C. to 13° C.). This ribbon was utilized for encapsulation of above mentioned Alendronate fill using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirements of current USP.
- a gel mass was made according to the formula below.
- the acid-insoluble polymer, EUDRAGIT L 100 was dissolved in the water-alkali vehicle, triethyl citrate was then added.
- the film-forming polymer, gelatin (lime bone, 150 bloom) was mixed with the plasticizer, glycerol. And added to the enteric polymer solution, mixed for 2 hours and was kept overnight at 60° C.
- Example 6 Gel mass of Example 6 was cast into a ribbon with 0.03′′ thickness on a cold drum (10° C. to 13° C.). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 12 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
- Gel mass of example 6 was cast into a ribbon with 0.025′′ thickness on a cold drum (10° C. to 13° C.). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 12 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
- Gel mass of example 6 was cast into a ribbon with 0.020′′ thickness on a cold drum (10° C. to 13° C.). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 12 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
- Gel mass of example 6 was cast into a ribbon with 0.015′′ thickness on a cold drum (10° C. to 13° C.). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 12 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
- a gel mass was made according to the formula below.
- the acid-insoluble polymer, EUDRAGIT L 100 was dissolved in the water-alkali vehicle, triethyl citrate was then added.
- the film-forming polymer, gelatin (lime bone, 150 bloom) was mixed with the plasticizer, glycerol. And added to the enteric polymer solution, mixed for 2 hours and was kept overnight at 60° C.
- Example 13 Gel mass of Example 13 was cast into a ribbon with 0.050′′ thickness on a cold drum (10° C. to 13° C.). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
- Example 13 Gel mass of Example 13 was cast into a ribbon with 0.045′′ thickness on a cold drum (10° C. to 13° C.). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
- Gel mass of example 13 was cast into a ribbon with 0.040′′ thickness on a cold drum (10° C. to 13° C.). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
- Example 13 Gel mass of Example 13 was cast into a ribbon with 0.035′′ thickness on a cold drum (10° C. to 13° C.). This ribbon was utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
- Example 13 Gel mass of Example 13 was cast into a ribbon with 0.030′′ thickness on a cold drum (10° C. to 13° C.). This ribbon is utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
- Example 13 Gel mass of Example 13 was cast into a ribbon with 0.025′′ thickness on a cold drum (10° C. to 13° C.). This ribbon is utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
- Example 13 Gel mass of Example 13 was cast into a ribbon with 0.020′′ thickness on a cold drum (10° C. to 13° C.). This ribbon is utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
- Example 13 Gel mass of Example 13 was cast into a ribbon with 0.015′′ thickness on a cold drum (10° C. to 13° C.). This ribbon is utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
- Garlic extract was mixed with soybean oil at 200 rpm using a propeller mixer.
- Example 13 Garlic extract 0.32% Soybean Oil 99.68% Gel mass of Example 13 was cast into a ribbon with 0.03′′ thickness on a cold drum (10° C. to 13° C.). This ribbon was utilized for encapsulation of above-mentioned garlic fill using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirements of current USP.
- Vitamin E TPGS and CREMOPHOR RH40 were melted with medium chain triglyceride at 40° C. Omeprazole was added to the above mixture and mixed well.
- Example 13 Gel mass of Example 13 was casted as a ribbon with 0.03′′ thickness on a cold drum (10° C. to 13° C.). This ribbon is utilized for encapsulation of above mentioned Omeprazole fill using 3 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirements of current USP.
- a gel mass was made according to the formula below.
- the acid-insoluble polymer, EUDRAGIT L 100 was dissolved in the water-alkali vehicle, triethyl citrate was then added.
- the film-forming polymer, gelatin (lime bone, 150 bloom) was mixed with the plasticizer, glycerol. And added to the enteric polymer solution, mixed for 2 hours and was kept overnight at 60° C.
- Example 24 Gel mass of Example 24 was cast into a ribbon with 0.030′′ thickness on a cold drum (10° C. to 13° C.). This ribbon is utilized for encapsulation of medium chain tryiglyceride oil using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirement of current USP.
- Acetic acid was added to polyethylene glycol (400) and mixed well.
- Bisacodyl was added to the polyethylene glycol/acetic acid mixture and mixed using a propeller mixture at 60° C. for 30 minutes (till completely dissolved).
- Example 23 Gel mass of Example 23 was cast into a ribbon with 0.03′′ thickness on a cold drum (10° C. to 13° C.). This ribbon was utilized for encapsulation of above-mentioned Bisacodyl fill using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirements of current USP.
- Vegetable shortening, hydrogenated vegetable oil, and beeswax were melted with soybean oil at 65° C.
- Bisacodyl was added and mixed using a propeller mixer and the mix is cooled back to room temperature.
- Example 24 Gel mass of Example 24 was cast into a ribbon with 0.03′′ thickness on a cold drum (10 to 13° C.). This ribbon was utilized for encapsulation of above-mentioned Bisacodyl fill using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirements of current USP.
- Methylene blue (water soluble dye) was dissolved in 0.1 N HCl placed on one side of the chamber and plain 0.1 N HCl on the other side of the chamber separated using enteric gel mass according to Example 1. This setup was placed in shaking water bath at 37° C., samples were removed up to 2 hours at periodic time intervals of 10, 20, 30, 45, 60, 90 and 120 minutes.
- An 80:20 gelatin-to-polymer ratio gel mass was manufactured to verify the feasibility in the pilot gel reactor.
- the resulting gel mass was encapsulated at different ribbon thickness such as 0.015′′, 0.025′′ and 0.030′′ with two different speeds such as 3.0 and 3.5 RPM.
- the 0.040′′ ribbon thickness capsules exhibited no swelling and stayed intact in SGF; they dissolved between 30 and 60 minutes in SIF. Thinner ribbons were also used for the same formula as shown in Table 1.
- a gel mass was made according to the formula below.
- the acid-insoluble polymer, (CAP) was dissolved in the water-alkali vehicle, and triethyl citrate was then added.
- the film-forming polymer, gelatin (lime bone, 150 bloom) was mixed with the plasticizer, glycerol, and added to the enteric polymer solution, mixed for 2 hours and kept overnight at 60° C.
- a gel mass was made according to the formula below.
- the acid-insoluble polymer, CAP was dissolved in the water-alkali vehicle, and triethyl citrate was then added.
- the film-forming polymer, gelatin (lime bone, 150 bloom) was mixed with the plasticizer, glycerol, and added to the enteric polymer solution, mixed for 2 hours and kept overnight at 60° C.
- a gel mass was made according to the formula below.
- the acid-insoluble polymer shellac was dissolved in the water-alkali vehicle, and triethyl citrate was then added.
- the film-forming polymer, gelatin (lime bone, 150 bloom) was mixed with the plasticizer, glycerol, and added to the enteric polymer solution, mixed for 2 hours and kept overnight at 60° C.
- Enteric aspirin tablets were made using the enteric gel mass of Example 24 and a rotary die machine as per the process described in U.S. Pat. Nos. 5,459,983, 5,146,730 and 6,482,516.
Abstract
Description
Gelatin | 36.00% | ||
EUDRAGIT L 100 | 9.00% | ||
Glycerol | 18.00% | ||
Triethyl citrate | 0.90% | ||
Ammonium Hydroxide (30% w/v) | 2.40% | ||
Water | 33.70% | ||
Alendronate Sodium | 1.54% | ||
Hydrogenated Soybean Oil | 7.45% | ||
Soybean Oil | 83.55% | ||
Hydrogenated soybean oil was melted at 65° C. with soybean oil and to this mixture, Alendronate sodium was added and mixed using homogenizer at 1000 rpm for 5 minutes.
Alendronate Sodium | 1.26% | ||
Polyethylene glycol (3350) | 4.94% | ||
Polyethylene glycol (400) | 93.80% | ||
Polyethylene glycol was melted at 55° C. with polyethylene glycol (400) and to this mixture, Alendronate sodium was added and mixed using a homogenizer at 1000 rpm for 5 minutes.
Alendronate Sodium | 1.26% | ||
Water | 10.00% | ||
Hydrogenated Soybean Oil | 7.47% | ||
Vegetable Shortening | 7.47% | ||
Soybean Oil | 73.50% | ||
Alendronate sodium was dissolved in water (part 1). Hydrogenated soybean oil and vegetable shortening was melted at 65° C. with soybean oil (art 2). Part 1 and 2 is mixed and passed five times through the MICROFLUIDIZER® at 10,000 psi.
Gelatin | 36.00% | ||
EUDRAGIT L 100 | 9.00% | ||
Glycerol | 18.00% | ||
Triethyl citrate | 0.90% | ||
Sodium Hydroxide | 2.80% | ||
Water | 33.30% | ||
Gelatin | 31.50% | ||
EUDRAGIT L 100 | 13.50% | ||
Glycerol | 17.55% | ||
Triethyl citrate | 1.35% | ||
Ammonium Hydroxide (30% w/v) | 3.60% | ||
Water | 32.50% | ||
Garlic extract | 0.32% | ||
Soybean Oil | 99.68% | ||
Gel mass of Example 13 was cast into a ribbon with 0.03″ thickness on a cold drum (10° C. to 13° C.). This ribbon was utilized for encapsulation of above-mentioned garlic fill using 7.5 oval die. The capsules were dried and subjected for dissolution/disintegration analysis as per the requirements of current USP.
Omeprazole | 7.40% | ||
Medium chain triglyceride | 63.00% | ||
Vitamin E TPGS | 7.40% | ||
Cremophor RH 40 | 22.20% | ||
Gelatin | 27.00% | ||
EUDRAGIT L 100 | 18.00% | ||
Glycerol | 17.10% | ||
Triethyl citrate | 1.80% | ||
Ammonium Hydroxide (30% w/v) | 4.80% | ||
Water | 31.30% | ||
Bisacodyl | 1.40% | ||
Acetic acid | 1.00% | ||
Polyethylene glycol (400) | 97.60% | ||
Bisacodyl | 1.40% | ||
Vegetable Shortening | 10.00% | ||
Hydrogenated Soybean Oil | 2.50% | ||
Beeswax | 2.50% | ||
Soybean Oil | 83.60% | ||
TABLE 1 |
Example Parameter and Testing Summary |
Parameters |
Gelatin: | Cap- | Ribbon | USP Enteric | ||
Eudragit ® | Eudragit ® | sule | thick- | Disintegration Test |
No. | [A to B] | solubilizer | size | ness | Acid | pH 6.8 |
1 | 70:30 | NH4OH | 7.5 | 0.030″ | Pass | Pass |
oval | Intact | Disap- | ||||
capsules | peared | |||||
in 30 | ||||||
minutes | ||||||
2 | 70:30 | NH4OH | 7.5 | 0.025″ | Pass | Pass |
oval | Intact | Disap- | ||||
capsules | peared | |||||
in 30 | ||||||
minutes | ||||||
3 | 70:30 | NH4OH | 7.5 | 0.015″ | Pass | Pass |
oval | Intact | Disap- | ||||
capsules | peared | |||||
in 15 | ||||||
minutes | ||||||
Cellulose Acetate Phthalate as 30% W/V dispersion |
CPD - 30 | 13.30% | ||
Gelatin | 31.50% | ||
Triethyl Citrate | 1.35% | ||
Glycerol | 17.55% | ||
Ammonium Hydroxide | 1.48% | ||
Water | 34.82% | ||
Cellulose Acetate Phthalate as 30% W/V dispersion |
CPD - 30 | 13.18% | ||
Gelatin | 31.50% | ||
Triethyl Citrate | 1.35% | ||
Glycerol | 17.55% | ||
Sodium Hydroxide | 1.60% | ||
Water | 34.82% | ||
Ammoniated Shellac (25% W/V solution) | 36.00% | ||
Gelatin | 36.00% | ||
Glycerol | 18.00% | ||
Triethyl citrate | 0.90% | ||
Water | 9.10% | ||
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/529,984 US8685445B2 (en) | 2002-10-01 | 2003-06-27 | Enteric composition for the manufacture of soft capsule wall |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41518702P | 2002-10-01 | 2002-10-01 | |
US60415187 | 2002-10-01 | ||
PCT/US2003/020579 WO2004030658A1 (en) | 2002-10-01 | 2003-06-27 | Enteric composition for the manufacture of soft capsule wall |
US10/529,984 US8685445B2 (en) | 2002-10-01 | 2003-06-27 | Enteric composition for the manufacture of soft capsule wall |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/020579 A-371-Of-International WO2004030658A1 (en) | 2002-10-01 | 2003-06-27 | Enteric composition for the manufacture of soft capsule wall |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/693,332 Continuation US9254270B2 (en) | 2002-10-01 | 2012-12-04 | Enteric soft capsules |
US14/228,387 Continuation US9433585B2 (en) | 2002-10-01 | 2014-03-28 | Enteric soft capsules |
Publications (2)
Publication Number | Publication Date |
---|---|
US20060165778A1 US20060165778A1 (en) | 2006-07-27 |
US8685445B2 true US8685445B2 (en) | 2014-04-01 |
Family
ID=32069824
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/529,984 Active 2030-11-14 US8685445B2 (en) | 2002-10-01 | 2003-06-27 | Enteric composition for the manufacture of soft capsule wall |
US14/228,387 Expired - Lifetime US9433585B2 (en) | 2002-10-01 | 2014-03-28 | Enteric soft capsules |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/228,387 Expired - Lifetime US9433585B2 (en) | 2002-10-01 | 2014-03-28 | Enteric soft capsules |
Country Status (14)
Country | Link |
---|---|
US (2) | US8685445B2 (en) |
EP (2) | EP1545475B1 (en) |
JP (1) | JP5248739B2 (en) |
CN (1) | CN1688294A (en) |
AU (1) | AU2003299191A1 (en) |
CA (1) | CA2500663C (en) |
CY (1) | CY1118258T1 (en) |
DK (2) | DK1545475T3 (en) |
ES (2) | ES2609059T3 (en) |
HU (1) | HUE031650T2 (en) |
MX (1) | MXPA05003524A (en) |
PT (2) | PT2772250T (en) |
SI (2) | SI1545475T1 (en) |
WO (1) | WO2004030658A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US9326965B2 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US9566259B1 (en) | 2015-08-31 | 2017-02-14 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US9775814B2 (en) | 2014-06-20 | 2017-10-03 | Patheon Softgels Inc. | Enteric soft capsule compositions |
US9782374B2 (en) | 2014-06-23 | 2017-10-10 | Patheon Softgels Inc. | All-natural enteric soft capsules |
EP3272341A1 (en) | 2016-03-30 | 2018-01-24 | Gdanski Uniwersytet Medyczny | Enteric elastic films for the production of capsules |
US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
US10182993B2 (en) | 2015-04-06 | 2019-01-22 | Patheon Softgels Inc. | Compositions for colonic delivery of drugs |
US10182992B2 (en) | 2014-04-07 | 2019-01-22 | Patheon Softgels Inc. | Abuse-deterrent controlled release formulations |
US10772842B2 (en) | 2015-01-09 | 2020-09-15 | Patheon Softgels Inc. | Abuse-deterrent opioids |
WO2020225395A1 (en) | 2019-05-07 | 2020-11-12 | Bausch Health Ireland Limited | Liquid oral dosage formulations of methylnaltrexone |
WO2021224138A1 (en) | 2020-05-02 | 2021-11-11 | Bausch Health Ireland Limited | Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone |
US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070082046A1 (en) * | 2005-10-11 | 2007-04-12 | Banner Pharmacaps, Inc. | Enteric valproic acid |
EP1959935A2 (en) | 2005-10-26 | 2008-08-27 | Banner Pharmacaps Inc. | Hydrophilic vehicle-based dual controlled release matrix system as capsule fill |
JP5406529B2 (en) | 2005-10-26 | 2014-02-05 | バナー ファーマキャプス, インコーポレイテッド | Dual controlled release matrix system based on lipophilic vehicle as capsule filler |
US20070148248A1 (en) | 2005-12-22 | 2007-06-28 | Banner Pharmacaps, Inc. | Gastric reflux resistant dosage forms |
JP5183104B2 (en) * | 2006-06-19 | 2013-04-17 | 森下仁丹株式会社 | Multiple soft capsules for bad breath removal |
GB0706178D0 (en) * | 2007-03-29 | 2007-05-09 | Univ Aston | Enteric pharmaceutical capsules |
EP2219621B1 (en) | 2007-11-12 | 2013-12-25 | Pharmaceutics International, Inc. | Tri-molecular complexes and their use in drug delivery systems |
EP2223685A4 (en) * | 2007-11-13 | 2013-08-21 | Shanghai Huiyuan Vegetal Capsule Co Ltd | Non-gelatin enteric hard capsule shell and preparation method thereof |
WO2010042499A1 (en) | 2008-10-06 | 2010-04-15 | Banner Pharmacaps, Inc. | Stable solutions of orlistat for pharmaceutical dosage forms |
CA2746887C (en) | 2008-12-15 | 2016-07-05 | Banner Pharmacaps, Inc. | Methods for enhancing the release and absorption of water insoluble active agents |
US9011908B2 (en) | 2009-04-06 | 2015-04-21 | Banner Life Sciences Llc | Progesterone solutions for increased bioavailability |
EP2533770B1 (en) * | 2010-02-12 | 2017-10-04 | Sensient Colors LLC | Enteric coating compositions and method of making the same |
EP2632584B1 (en) | 2010-10-26 | 2017-08-09 | Capsugel Belgium NV | A process for the manufacture of bulk enteric capsule shells |
WO2013164121A1 (en) | 2012-05-02 | 2013-11-07 | Capsugel France SAS | Aqueous dispersions of hydroxypropyl methylcellulose acetate succinate (hpmcas) |
EP2968081A4 (en) | 2013-03-15 | 2016-08-10 | Banner Life Sciences Llc | Non-gelatin enteric soft capsules |
AU2013387678B2 (en) * | 2013-04-23 | 2015-04-16 | Sociétés des Produits Nestlé S.A. | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
US9504656B2 (en) | 2013-10-21 | 2016-11-29 | Banner Life Sciences, LLC | Pharmaceutical compositions for poorly soluble active ingredients |
EP3738586A1 (en) | 2013-10-30 | 2020-11-18 | Patheon Softgels Inc. | Enteric soft capsules comprising polyunsaturated fatty acids |
EP3065720A1 (en) * | 2013-11-04 | 2016-09-14 | Capsugel Belgium NV | Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole |
CA2950444C (en) * | 2014-06-26 | 2021-01-12 | Banner Life Sciences Llc | Enhanced bioavailability of polyunsaturated fatty acids |
US9895333B2 (en) * | 2014-06-26 | 2018-02-20 | Patheon Softgels Inc. | Enhanced bioavailability of polyunsaturated fatty acids |
US10471152B2 (en) | 2014-08-29 | 2019-11-12 | Capsugel Belgium Nv | Colloidal dispersion comprising HPMCAS |
AU2015329446B2 (en) | 2014-10-06 | 2017-03-16 | Fuji Capsule Co., Ltd. | Method of manufacturing enteric soft capsule |
CA2960620C (en) | 2014-10-06 | 2018-06-19 | Fuji Capsule Co., Ltd. | Method of manufacturing enteric seamless soft capsule |
CA2962916C (en) * | 2014-10-08 | 2021-06-15 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
US10363254B2 (en) * | 2015-03-31 | 2019-07-30 | University Of Vermont And State Agricultural College | Methods for treating cryptosporidiosis using triazolopyridazines |
WO2017136617A1 (en) | 2016-02-04 | 2017-08-10 | Cinrx Pharma, Llc | Deuterated domperidone compositions and methods for therapy of disorders |
NL2017219B1 (en) * | 2016-07-22 | 2018-01-30 | Rousselot B V | Low cross-linking gelatine |
EP3592337B1 (en) | 2017-03-08 | 2023-07-05 | Cinrx Pharma, LLC | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol |
US11364226B2 (en) | 2017-06-30 | 2022-06-21 | Cinrx Pharma, Llc | Deuterated domperidone compositions, methods, and preparation |
CN108619523B (en) * | 2018-03-23 | 2020-06-30 | 浙江工业大学 | Coated film for rapid thermoplastic coating preparation and preparation method thereof |
WO2020144591A2 (en) * | 2019-01-09 | 2020-07-16 | Antony Benny | Preparation of purified withanoside x from withania somnifera plant materials and its medicinal use for the treatment of health disorders |
CN109566829A (en) * | 2019-02-11 | 2019-04-05 | 广东国方医药科技有限公司 | Peony seed oil enteric gel candy and preparation method thereof |
US11547714B2 (en) | 2020-02-05 | 2023-01-10 | Epalex Corporation | Fospropofol salts, methods and compositions |
US11439653B1 (en) | 2021-03-30 | 2022-09-13 | Epalex Corporation | Fospropofol formulations |
US11478490B1 (en) | 2021-03-30 | 2022-10-25 | Epalex Corporation | Fospropofol formulations |
US11628178B2 (en) | 2019-03-26 | 2023-04-18 | Epalex Corporation | Fospropofol methods and compositions |
EP3999013A4 (en) * | 2019-07-15 | 2023-07-26 | R.P. Scherer Technologies, LLC | Enteric proton pump inhibitor softgel capsule |
CA3119012C (en) * | 2021-05-18 | 2023-10-17 | Gelentroceutics Inc. | Formulation of intrinsically acid-resistant vegetarian-based and gelatin-based soft gel capsules for pharmaceutical/nutraceutical products |
WO2023250297A1 (en) | 2022-06-21 | 2023-12-28 | Nutrition & Biosciences Usa 1, Llc | Film forming delayed/enteric formulations for hard shell capsules, films and coatings |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3826666A (en) * | 1972-07-20 | 1974-07-30 | Parke Davis & Co | Enteric capsules |
US4138013A (en) * | 1976-08-27 | 1979-02-06 | Parke, Davis & Company | Enteric capsules |
EP0092908A2 (en) | 1982-03-26 | 1983-11-02 | Warner-Lambert Company | Hydrophilic polymer composition for injection molding |
DE3222476A1 (en) | 1982-06-15 | 1983-12-15 | Warner-Lambert Co., 07950 Morris Plains, N.J. | Soft gelatin capsules resistant to gastric fluid, and process for the production thereof |
US4500453A (en) * | 1984-06-29 | 1985-02-19 | Dynagel Incorporated | Cross-linked protein composition using aluminum salts of acetic acid |
US4790881A (en) | 1982-03-26 | 1988-12-13 | Warner-Lambert Company | Molded hydrophilic polymer |
US4816259A (en) * | 1987-02-12 | 1989-03-28 | Chase Chemical Company, L.P. | Process for coating gelatin capsules |
US5194464A (en) * | 1988-09-27 | 1993-03-16 | Takeda Chemical Industries, Ltd. | Enteric film and preparatoin thereof |
WO1998050019A1 (en) | 1997-05-09 | 1998-11-12 | Sage Pharmaceuticals, Inc. | Stable oral pharmaceutical dosage forms |
WO2000067723A2 (en) | 1999-05-10 | 2000-11-16 | Roland Bodmeier | Form of administration for applying in body orifices |
WO2001024780A2 (en) | 1999-10-01 | 2001-04-12 | Natco Pharma Limited | Soft gel capsule resistant to gastric juices |
US20010051188A1 (en) * | 1998-05-22 | 2001-12-13 | Ismat Ullah | High drug load acid labile pharmaceutical composition |
US6331316B1 (en) * | 1998-07-17 | 2001-12-18 | Bristol-Myers Squibb Company | Enteric coated pharmaceutical tablet and method of manufacturing |
EP1184033A1 (en) | 2000-09-01 | 2002-03-06 | Warner-Lambert Company | Pectin film compositions |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2340060A1 (en) * | 1973-08-08 | 1975-02-20 | Scherer Gmbh R P | GELATINE RESISTANT CAPSULES AND METHOD FOR MANUFACTURING THEREOF |
US4518433A (en) | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
US6482516B1 (en) | 1993-07-20 | 2002-11-19 | Banner Pharmacaps, Inc. | Enrobed tablet |
US5146730A (en) | 1989-09-20 | 1992-09-15 | Banner Gelatin Products Corp. | Film-enrobed unitary-core medicament and the like |
US5330759A (en) | 1992-08-26 | 1994-07-19 | Sterling Winthrop Inc. | Enteric coated soft capsules and method of preparation thereof |
US6193999B1 (en) * | 1999-03-01 | 2001-02-27 | Banner Pharmacaps, Inc. | Gum acacia substituted soft gelatin capsules |
WO2004012701A2 (en) * | 2002-08-02 | 2004-02-12 | Scitech Centre | NOVEL pH DEPENDENT ROBUST ENTERIC POLYMERIC CONTAINER, AN IMPROVEMENT OVER EXISTING ENTERIC DOSAGE FORMS. |
-
2003
- 2003-06-27 PT PT141704924T patent/PT2772250T/en unknown
- 2003-06-27 AU AU2003299191A patent/AU2003299191A1/en not_active Abandoned
- 2003-06-27 US US10/529,984 patent/US8685445B2/en active Active
- 2003-06-27 SI SI200332379T patent/SI1545475T1/en unknown
- 2003-06-27 CN CNA038235579A patent/CN1688294A/en active Pending
- 2003-06-27 PT PT37423365T patent/PT1545475E/en unknown
- 2003-06-27 CA CA2500663A patent/CA2500663C/en not_active Expired - Lifetime
- 2003-06-27 ES ES14170492.4T patent/ES2609059T3/en not_active Expired - Lifetime
- 2003-06-27 EP EP03742336.5A patent/EP1545475B1/en not_active Expired - Lifetime
- 2003-06-27 EP EP14170492.4A patent/EP2772250B1/en not_active Expired - Lifetime
- 2003-06-27 WO PCT/US2003/020579 patent/WO2004030658A1/en active Application Filing
- 2003-06-27 JP JP2004541451A patent/JP5248739B2/en not_active Expired - Lifetime
- 2003-06-27 HU HUE14170492A patent/HUE031650T2/en unknown
- 2003-06-27 SI SI200332504A patent/SI2772250T1/en unknown
- 2003-06-27 DK DK03742336.5T patent/DK1545475T3/en active
- 2003-06-27 DK DK14170492.4T patent/DK2772250T3/en active
- 2003-06-27 ES ES03742336.5T patent/ES2500316T3/en not_active Expired - Lifetime
- 2003-06-27 MX MXPA05003524A patent/MXPA05003524A/en active IP Right Grant
-
2014
- 2014-03-28 US US14/228,387 patent/US9433585B2/en not_active Expired - Lifetime
-
2016
- 2016-11-21 CY CY20161101198T patent/CY1118258T1/en unknown
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3826666A (en) * | 1972-07-20 | 1974-07-30 | Parke Davis & Co | Enteric capsules |
US4138013A (en) * | 1976-08-27 | 1979-02-06 | Parke, Davis & Company | Enteric capsules |
EP0092908A2 (en) | 1982-03-26 | 1983-11-02 | Warner-Lambert Company | Hydrophilic polymer composition for injection molding |
US4790881A (en) | 1982-03-26 | 1988-12-13 | Warner-Lambert Company | Molded hydrophilic polymer |
DE3222476A1 (en) | 1982-06-15 | 1983-12-15 | Warner-Lambert Co., 07950 Morris Plains, N.J. | Soft gelatin capsules resistant to gastric fluid, and process for the production thereof |
US4500453A (en) * | 1984-06-29 | 1985-02-19 | Dynagel Incorporated | Cross-linked protein composition using aluminum salts of acetic acid |
US4816259A (en) * | 1987-02-12 | 1989-03-28 | Chase Chemical Company, L.P. | Process for coating gelatin capsules |
US5194464A (en) * | 1988-09-27 | 1993-03-16 | Takeda Chemical Industries, Ltd. | Enteric film and preparatoin thereof |
WO1998050019A1 (en) | 1997-05-09 | 1998-11-12 | Sage Pharmaceuticals, Inc. | Stable oral pharmaceutical dosage forms |
US20010051188A1 (en) * | 1998-05-22 | 2001-12-13 | Ismat Ullah | High drug load acid labile pharmaceutical composition |
US6331316B1 (en) * | 1998-07-17 | 2001-12-18 | Bristol-Myers Squibb Company | Enteric coated pharmaceutical tablet and method of manufacturing |
WO2000067723A2 (en) | 1999-05-10 | 2000-11-16 | Roland Bodmeier | Form of administration for applying in body orifices |
WO2001024780A2 (en) | 1999-10-01 | 2001-04-12 | Natco Pharma Limited | Soft gel capsule resistant to gastric juices |
EP1184033A1 (en) | 2000-09-01 | 2002-03-06 | Warner-Lambert Company | Pectin film compositions |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
US9326965B2 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US9511043B2 (en) | 2014-02-28 | 2016-12-06 | Banner Life Sciences Llc | Fumarate ester pharmaceutical compositions |
US9517209B2 (en) | 2014-02-28 | 2016-12-13 | Banner Life Sciences Llc | Fumarate ester pharmaceutical compositions |
US10918616B2 (en) | 2014-02-28 | 2021-02-16 | Banner Life Sciences Llc | Fumarate ester pharmaceutical compositions |
US10918617B2 (en) | 2014-02-28 | 2021-02-16 | Banner Life Sciences Llc | Fumarate ester pharmaceutical compositions |
US10918615B2 (en) | 2014-02-28 | 2021-02-16 | Banner Life Sciences Llc | Fumarate esters |
EP3766487A1 (en) | 2014-02-28 | 2021-01-20 | Banner Life Sciences LLC | Controlled release enteric soft capsules of fumarate esters |
US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US9814691B2 (en) | 2014-02-28 | 2017-11-14 | Banner Life Sciences Llc | Fumarate ester pharmaceutical compositions |
EP3501510A1 (en) | 2014-02-28 | 2019-06-26 | Banner Life Sciences LLC | Controlled release enteric soft capsules of fumarate esters |
US10105336B2 (en) | 2014-02-28 | 2018-10-23 | Banner Life Sciences Llc | Fumarate ester pharmaceutical compositions |
US9820960B2 (en) | 2014-02-28 | 2017-11-21 | Banner Life Sciences Llc | Fumarate ester pharmaceutical compositions |
US10105337B2 (en) | 2014-02-28 | 2018-10-23 | Banner Life Sciences Llc | Fumarate ester pharmaceutical compositions |
US10772841B2 (en) | 2014-04-07 | 2020-09-15 | Patheon Softgels Inc. | Opioid abuse-deterrent controlled release formulations |
US10182992B2 (en) | 2014-04-07 | 2019-01-22 | Patheon Softgels Inc. | Abuse-deterrent controlled release formulations |
US10226432B2 (en) | 2014-06-20 | 2019-03-12 | Patheon Softgels Inc. | Enteric soft capsule compositions |
US9775814B2 (en) | 2014-06-20 | 2017-10-03 | Patheon Softgels Inc. | Enteric soft capsule compositions |
US9987240B2 (en) | 2014-06-23 | 2018-06-05 | Patheon Softgels, Inc. | All-natural enteric soft capsules |
US9782374B2 (en) | 2014-06-23 | 2017-10-10 | Patheon Softgels Inc. | All-natural enteric soft capsules |
US10357467B2 (en) | 2014-06-23 | 2019-07-23 | Patheon Softgels, Inc. | All-natural enteric soft capsules |
US10772842B2 (en) | 2015-01-09 | 2020-09-15 | Patheon Softgels Inc. | Abuse-deterrent opioids |
US10182993B2 (en) | 2015-04-06 | 2019-01-22 | Patheon Softgels Inc. | Compositions for colonic delivery of drugs |
US9636319B1 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US10105335B2 (en) | 2015-08-31 | 2018-10-23 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US9820961B2 (en) | 2015-08-31 | 2017-11-21 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US9814692B2 (en) | 2015-08-31 | 2017-11-14 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US9566259B1 (en) | 2015-08-31 | 2017-02-14 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US10945985B2 (en) | 2015-08-31 | 2021-03-16 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US11590095B2 (en) | 2015-08-31 | 2023-02-28 | Banner Life Sciences Llc | Fumarate ester dosage forms |
EP3272341A1 (en) | 2016-03-30 | 2018-01-24 | Gdanski Uniwersytet Medyczny | Enteric elastic films for the production of capsules |
WO2020225395A1 (en) | 2019-05-07 | 2020-11-12 | Bausch Health Ireland Limited | Liquid oral dosage formulations of methylnaltrexone |
US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
WO2021224138A1 (en) | 2020-05-02 | 2021-11-11 | Bausch Health Ireland Limited | Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone |
Also Published As
Publication number | Publication date |
---|---|
AU2003299191A1 (en) | 2004-04-23 |
SI2772250T1 (en) | 2017-03-31 |
CN1688294A (en) | 2005-10-26 |
CA2500663A1 (en) | 2004-04-15 |
ES2609059T3 (en) | 2017-04-18 |
JP5248739B2 (en) | 2013-07-31 |
US20140348879A1 (en) | 2014-11-27 |
DK2772250T3 (en) | 2016-12-05 |
WO2004030658A1 (en) | 2004-04-15 |
ES2500316T3 (en) | 2014-09-30 |
HUE031650T2 (en) | 2017-07-28 |
JP2006505542A (en) | 2006-02-16 |
PT1545475E (en) | 2014-09-16 |
MXPA05003524A (en) | 2005-10-04 |
US20060165778A1 (en) | 2006-07-27 |
EP1545475B1 (en) | 2014-07-16 |
EP2772250A1 (en) | 2014-09-03 |
CA2500663C (en) | 2013-05-28 |
DK1545475T3 (en) | 2014-07-28 |
CY1118258T1 (en) | 2017-06-28 |
US9433585B2 (en) | 2016-09-06 |
SI1545475T1 (en) | 2014-10-30 |
EP2772250B1 (en) | 2016-09-28 |
PT2772250T (en) | 2017-01-02 |
EP1545475A1 (en) | 2005-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8685445B2 (en) | Enteric composition for the manufacture of soft capsule wall | |
DE69918703T2 (en) | FILM-FORMING COMPOSITIONS FROM MODIFIED STARCH | |
JP4638046B2 (en) | Edible coating composition | |
US9700517B2 (en) | Acid resistant capsules | |
CA2625554C (en) | Enteric soft capsule comprising valproic acid | |
JP7198205B2 (en) | Enteric coated hard capsule | |
EP3205339B1 (en) | Method of manufacturing enteric seamless soft capsule | |
US20220354800A1 (en) | Delayed release softgel capsules | |
JP2003527335A (en) | Edible coating composition | |
US20070099843A1 (en) | Nutritional supplement for the enhancement of the health of the liver | |
KR20230106641A (en) | Delayed-release softgel capsules | |
US9254270B2 (en) | Enteric soft capsules | |
JP2023532180A (en) | Delayed release softgel capsule | |
JP2022123274A (en) | Enteric-coated hard capsule | |
WO2005092296A1 (en) | Edible microcrystalline cellulose and carrageenan coating composition | |
TW202233164A (en) | Delayed release softgel capsules | |
JP2022525180A (en) | Capsule shell containing core-shell polymer and cellulose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BANNER PHARMACAPS, INC., NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FATMI, AQUEEL A.;HASSAN, EMADELDIN M.;CHIDAMBARAM, NACHIAPPAN;REEL/FRAME:016928/0712 Effective date: 20030616 |
|
AS | Assignment |
Owner name: BANNER PHARMACAPS, INC., NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HASSAN, EMADELDIN M.;FATMI, AQEEL A.;CHIDAMBARAM, NACHIAPPAN;REEL/FRAME:016018/0210 Effective date: 20030616 |
|
AS | Assignment |
Owner name: MORGAN STANLEY SENIOR FUNDING INC., AS COLLATERAL Free format text: SECURITY AGREEMENT;ASSIGNOR:BANNER PHARMACAPS INC.;REEL/FRAME:029481/0962 Effective date: 20121214 |
|
AS | Assignment |
Owner name: UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT, CONN Free format text: SECURITY INTEREST;ASSIGNOR:BANNER PHARMACAPS INC.;REEL/FRAME:032403/0790 Effective date: 20140311 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: BANNER PHARMACAPS INC., NORTH CAROLINA Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT RIGHTS;ASSIGNOR:MORGAN STANLEY SENIOR FUNDING, INC.;REEL/FRAME:032745/0454 Effective date: 20140311 |
|
AS | Assignment |
Owner name: BANNER LIFE SCIENCES LLC, NORTH CAROLINA Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:BANNER PHARMACAPS INC;REEL/FRAME:034294/0916 Effective date: 20141111 |
|
AS | Assignment |
Owner name: UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT, CONN Free format text: SECURITY INTEREST;ASSIGNOR:BANNER LIFE SCIENCES LLC;REEL/FRAME:035133/0328 Effective date: 20150305 |
|
AS | Assignment |
Owner name: BANNER LIFE SCIENCES LLC, NORTH CAROLINA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:UBS AG, STAMFORD BRANCH;REEL/FRAME:036239/0188 Effective date: 20150731 Owner name: BANNER PHARMACAPS INC., NORTH CAROLINA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:UBS AG, STAMFORD BRANCH;REEL/FRAME:036224/0623 Effective date: 20150731 Owner name: BANNER LIFE SCIENCES LLC, NORTH CAROLINA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:UBS AG, STAMFORD BRANCH;REEL/FRAME:036224/0623 Effective date: 20150731 |
|
AS | Assignment |
Owner name: PATHEON SOFTGELS INC, NORTH CAROLINA Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:BANNER LIFE SCIENCES LLC;REEL/FRAME:043032/0619 Effective date: 20170622 |
|
AS | Assignment |
Owner name: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS SUCCES Free format text: NOTICE OF SUCCESSION OF AGENCY FOR PATENT SECURITY INTEREST PREVIOUSLY RECORDED AT REEL/FRAME (032403/0790);ASSIGNOR:UBS AG, STAMFORD BRANCH, AS PRIOR AGENT;REEL/FRAME:043173/0005 Effective date: 20170620 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551) Year of fee payment: 4 |
|
AS | Assignment |
Owner name: BANNER PHARMACAPS INC., NORTH CAROLINA Free format text: RELEASE (REEL 032403 / FRAME 0790);ASSIGNOR:CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH;REEL/FRAME:044038/0028 Effective date: 20170921 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |